Key result
Treatment with neoadjuvant chemotherapy, wide local excision, and radiotherapy resulted in complete tumor necrosis and no recurrence at eight months in a 12-year-old boy with BCOR-CCNB3 sarcoma.
Why the study?
BCOR-CCNB3 sarcoma, previously considered comparable to Ewing sarcoma, is now recognized as a distinct entity under undifferentiated round cell sarcomas.
Case Report (n=1)
No
BCOR-CCNB3 fusion sarcoma is a rare, distinct entity of undifferentiated round cell sarcoma that can be successfully managed with neoadjuvant chemotherapy, wide local excision, and radiotherapy.
Answers are grounded in this paper and cite their sources.
Suggests potential benefit of multimodal therapy in rare BCOR-CCNB3 sarcoma; leaves open confirmation in prospective studies.
In the past, BCOR-CCNB3 sarcoma was believed to be comparable to Ewing's sarcoma; however, current research has proven that it is, in reality, a distinct type of the illness, now classified as a distinct entity under undifferentiated round cell sarcomas. This tumour most frequently affects teenagers and young adults, and it is more prevalent in men. It can form in both bone and soft tissue, and it appears most frequently in the pelvis, lower extremities, and paraspinal region. Here, we describe a case of a soft tissue tumour in the proximal posterior portion of the right thigh of a 12-year-old male that was subsequently shown to be a BCOR-CCNB3 fusion using genetic analysis.
No takes yet. Share an insight, caveat, or question.
Kedia et al. (2023) conducted a case report in BCOR-CCNB3 fusion sarcoma (n=1). Neoadjuvant chemotherapy, wide local excision, and radiotherapy was evaluated on Tumor recurrence. Treatment with neoadjuvant chemotherapy, wide local excision, and radiotherapy resulted in complete tumor necrosis and no recurrence at eight months in a 12-year-old boy with BCOR-CCNB3 sarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: